PAMS
VKTX icon

Pictet Asset Management (Switzerland)’s Viking Therapeutics VKTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$184K Hold
11,369
– – ﹤0.01% 1752
2023
Q1 		$189K Buy
+11,369
New +$117K ﹤0.01% 1752

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s VKTX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) held its Viking Therapeutics (VKTX) position steady in Q2 2023 at 11,369 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #1752.

Pictet Asset Management (Switzerland) first reported a position in VKTX in Q1 2023 and has held it in 2 quarters since. The position peaked at $189K in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 11,369 shares of Viking Therapeutics worth $184K as of Q2 2023.
  • Pictet Asset Management (Switzerland) left its Viking Therapeutics share count unchanged in Q2 2023.
  • Viking Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1752 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Viking Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • Pictet Asset Management (Switzerland)'s Viking Therapeutics position peaked at $189K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.